Regulatory Story
Company AorTech International PLC
Headline Result of AGM
Released 14:53 19-Aug-2019
Number 5270J

RNS Number : 5270J
AorTech International PLC
19 August 2019

19 August 2019


AorTech International plc



Result of AGM


AorTech International plc (AIM: AOR), the biomaterials IP and medical device development company, announces that all resolutions put to shareholders at its Annual General Meeting held earlier today, were duly passed.



For further information contact:


AorTech International plc                                                                     Tel: +44 (0)7730 718296

Bill Brown, Chairman                                                                   


Shore Capital                                                                                          Tel: +44 (0)20 7408 4080

Tom Griffiths/David Coaten                                                         



About AorTech:


AorTech has developed biostable, implantable polymers, including Elast-Eon™ and ECSil™ the world's leading long-term implantable co-polymers, now manufactured on its behalf by Biomerics LLC in Utah, USA. Elast-Eon™ and ECSil™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 6 million implants and over 10 years of successful clinical use AorTech polymers are proven in long term life enabling applications.


In addition to continuing to exploit AorTech's Intellectual Property related to the world class biomaterial - Elast-Eon™, AorTech is now incorporating this material into a number of medical devices of our own design. Elast-Eon™ has first class long term blood contacting properties and as a result, all of the initial products being developed are for the cardio vascular field. Each device is being designed to have improved clinical outcomes over current device technology,eliminating the use of animal sourced material whilst allowing procedures to remain the same, therefore avoiding the need of having to retrain surgeons in new ways of operating.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit
London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.